...
search icon
vinc-img

Vincerx Pharma, Inc. Common Stock, Common Stock

VINC

NASDAQ

$0.05

-$0.01

(-16.67%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$275.85K
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
4.60K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.52

About Vincerx Pharma, Inc. Common Stock, Common Stock

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop ADCs and SMDCs; and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory AML, higher-risk MDS, and B-ALL; VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies; VIP236, a small molecule-drug conjugate, which is in Phase 1 dose-escalation study in patients with advanced or metastatic solid tumors; and Enitociclib, a highly selective CDK9 inhibitor, which is in Phase 1 clinical trial. Vincerx Pharma, Inc. was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. The company was founded in 2019 and is based in San Mateo, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVINCSectorS&P500
1-Week Return12.99%-3.17%-0.26%
1-Month Return-78.23%-3.33%4.06%
3-Month Return-95.68%-8.31%-6.62%
6-Month Return-99.15%-10.15%-5.64%
1-Year Return-99.65%-6.39%8.61%
3-Year Return-99.86%6.11%41.93%
5-Year Return-99.97%32.65%93.19%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue173.00K340.00K939.00K915.00K-[{"date":"2020-12-31","value":18.42,"profit":true},{"date":"2021-12-31","value":36.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.44,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(173.00K)(340.00K)(939.00K)(915.00K)-[{"date":"2020-12-31","value":-17299600,"profit":false},{"date":"2021-12-31","value":-34000000,"profit":false},{"date":"2022-12-31","value":-93900000,"profit":false},{"date":"2023-12-31","value":-91500000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses10.71M62.66M71.11M42.61M31.46M[{"date":"2020-12-31","value":15.07,"profit":true},{"date":"2021-12-31","value":88.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.92,"profit":true},{"date":"2024-12-31","value":44.25,"profit":true}]
Operating Income(10.71M)(62.66M)(73.57M)(42.61M)(31.46M)[{"date":"2020-12-31","value":-1071400000,"profit":false},{"date":"2021-12-31","value":-6265600000,"profit":false},{"date":"2022-12-31","value":-7357400000,"profit":false},{"date":"2023-12-31","value":-4260900000,"profit":false},{"date":"2024-12-31","value":-3146300000,"profit":false}]
Total Non-Operating Income/Expense(16.00K)23.35M8.87M3.96M1.86M[{"date":"2020-12-31","value":-0.07,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":37.99,"profit":true},{"date":"2023-12-31","value":16.98,"profit":true},{"date":"2024-12-31","value":7.97,"profit":true}]
Pre-Tax Income(10.72M)(39.31M)(65.37M)(40.16M)(30.07M)[{"date":"2020-12-31","value":-1072200000,"profit":false},{"date":"2021-12-31","value":-3930600000,"profit":false},{"date":"2022-12-31","value":-6536700000,"profit":false},{"date":"2023-12-31","value":-4015700000,"profit":false},{"date":"2024-12-31","value":-3007400000,"profit":false}]
Income Taxes8.00K(23.70M)(8.21M)--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-296225,"profit":false},{"date":"2022-12-31","value":-102587.5,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(10.73M)(15.61M)(57.16M)--[{"date":"2020-12-31","value":-1073000000,"profit":false},{"date":"2021-12-31","value":-1560800000,"profit":false},{"date":"2022-12-31","value":-5716000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(10.72M)(39.31M)(65.37M)(48.85M)(30.07M)[{"date":"2020-12-31","value":-1072200000,"profit":false},{"date":"2021-12-31","value":-3930600000,"profit":false},{"date":"2022-12-31","value":-6536700000,"profit":false},{"date":"2023-12-31","value":-4885000000,"profit":false},{"date":"2024-12-31","value":-3007400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(10.73M)(15.61M)(57.16M)(40.16M)(30.07M)[{"date":"2020-12-31","value":-1073000000,"profit":false},{"date":"2021-12-31","value":-1560800000,"profit":false},{"date":"2022-12-31","value":-5716000000,"profit":false},{"date":"2023-12-31","value":-4015700000,"profit":false},{"date":"2024-12-31","value":-3007400000,"profit":false}]
EPS (Diluted)(2.38)(2.28)(3.12)(1.89)(16.02)[{"date":"2020-12-31","value":-238,"profit":false},{"date":"2021-12-31","value":-228,"profit":false},{"date":"2022-12-31","value":-312,"profit":false},{"date":"2023-12-31","value":-189,"profit":false},{"date":"2024-12-31","value":-1602.17,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VINC
Cash Ratio 0.94
Current Ratio 1.21

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VINC
ROA (LTM) -138.54%
ROE (LTM) -431.29%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VINC
Debt Ratio Lower is generally better. Negative is bad. 0.66
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VINC
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.11
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Vincerx Pharma, Inc. Common Stock share price today?

Vincerx Pharma, Inc. Common Stock (VINC) share price today is $0.05

Can Indians buy Vincerx Pharma, Inc. Common Stock shares?

Yes, Indians can buy shares of Vincerx Pharma, Inc. Common Stock (VINC) on Vested. To buy Vincerx Pharma, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VINC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Vincerx Pharma, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Vincerx Pharma, Inc. Common Stock (VINC) via the Vested app. You can start investing in Vincerx Pharma, Inc. Common Stock (VINC) with a minimum investment of $1.

How to invest in Vincerx Pharma, Inc. Common Stock shares from India?

You can invest in shares of Vincerx Pharma, Inc. Common Stock (VINC) via Vested in three simple steps:

  • Click on Sign Up or Invest in VINC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Vincerx Pharma, Inc. Common Stock shares
What is Vincerx Pharma, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Vincerx Pharma, Inc. Common Stock (VINC) is 0.11

What is the Market Cap of Vincerx Pharma, Inc. Common Stock?

The market capitalization of Vincerx Pharma, Inc. Common Stock (VINC) is $275.85K

What is Vincerx Pharma, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Vincerx Pharma, Inc. Common Stock is VINC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top